Profile
Brooks Rahmer is currently the Head-Investors Relations Contact at Rocket Pharmaceuticals, Inc. He previously worked as the Investor Relations Contact at MyoKardia, Inc. from 2019 to 2021.
Brooks Rahmer active positions
| Companies | Position | Start |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Former positions of Brooks Rahmer
| Companies | Position | End |
|---|---|---|
| MYOKARDIA, INC. | Investor Relations Contact | 2020-12-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ROCKET PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Brooks Rahmer
